Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

BACKGROUND: PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed strong antitumor activity in preclinical models of cisplatin-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Poveda, A., del Campo, J. M., Ray-Coquard, I., Alexandre, J., Provansal, M., Guerra Alía, E. M., Casado, A., Gonzalez-Martin, A., Fernández, C., Rodriguez, I., Soto, A., Kahatt, C., Fernández Teruel, C., Galmarini, C. M., Pérez de la Haza, A., Bohan, P., Berton-Rigaud, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452066/
https://www.ncbi.nlm.nih.gov/pubmed/28368437
http://dx.doi.org/10.1093/annonc/mdx111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452066/
https://www.ncbi.nlm.nih.gov/pubmed/28368437
http://dx.doi.org/10.1093/annonc/mdx111

Ejemplares similares